Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma

Pediatric Blood and Cancer

Volumn 58, Issue 3, 2012, Pages 327-333

  Rankin, Kenneth S ^a   Starkey, Mike ^b   Lunec, John ^a   Gerrand, Craig H ^a   Murphy, Sue ^b   Biswas, Swethajit ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ANIMAL HEALTH TRUST   (United Kingdom)

Author keywords

Canines; Comparative oncology; Humans; Osteosarcoma

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; BEVACIZUMAB; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CANCER VACCINE; CISPLATIN; CYTOTOXIC AGENT; DENOSUMAB; GROWTH FACTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; INTERLEUKIN 8; LIPOSOMAL MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MASITINIB; NANOPARTICLE; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; STAT3 INHIBITOR; STAT3 PROTEIN; TANOMASTAT; TOCERANIB; TRIPEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

AMPUTATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHROMOSOME ABERRATION; DOG; DRUG SAFETY; DRUG TARGETING; ENCAPSULATION; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HYPOXIA; IMMUNOMODULATION; LUNG METASTASIS; LYMPH NODE METASTASIS; NANOTECHNOLOGY; NEPHROTOXICITY; NONHUMAN; ONCOLOGY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SPECIES COMPARISON; TOXICITY TESTING; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; DRUG DISCOVERY; HUMANS; LIMB SALVAGE; MOLECULAR TARGETED THERAPY; OSTEOSARCOMA; PHYSIOLOGY, COMPARATIVE; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84855763261     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23341     Document Type: Review

References (89)

1. Mirabello L, Pfeiffer R, Murphy G, et al. Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control 2011; 22: 899-908.
2. Rosenberger JA, Pablo NV, Crawford PC. Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases (1996-2005). J Am Vet Med Assoc 2007; 231: 1076-1080.
3. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res 1991; 270: 159-168.
4. Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Res 2007; 27: 155-164.
5. LaRue SM, Withrow SJ, Powers BE, et al. Limb-sparing treatment for osteosarcoma in dogs. J Am Vet Med Assoc 1989; 195: 1734-1744.
6. Withrow SJ, Thrall DE, Straw RC, et al. Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 1993; 71: 2484-2490.
7. Paoloni M, Davis S, Lana S, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009; 10: 625.
8. Ru G, Terracini B, Glickman LT. Host related risk factors for canine osteosarcoma. Vet J 1998; 156: 31-39.
9. Phillips JC, Lembcke L, Chamberlin T. A novel locus for canine osteosarcoma (OSA1) maps to CFA34, the canine orthologue of human 3q26. Genomics 2010; 96: 220-227.
10. Kruzelock RP, Murphy EC, Strong LC, et al. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res 1997; 57: 106-109.
11. Tarkkanen M, Elomaa I, Blomqvist C, et al. DNA sequence copy number increase at 8q: A potential new prognostic marker in high-grade osteosarcoma. Int J Cancer 1999; 84: 114-121.
12. Bridge JA, Nelson M, McComb E, et al. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 1997; 95: 74-87.
13. Boehm A, Neff J, Squire J, et al. Cytogenetic findings in 36 osteosarcoma specimens and a review of the literature. Pediatr Pathol Mol Med 2000; 19: 359-376.
14. Ozaki T, Schaefer KL, Wai D, et al. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 2002; 102: 355-365.
15. Thomas R, Wang HJ, Tsai PC, et al. Influence of genetic background on tumor karyotypes: Evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Res 2009; 17: 365-377.
16. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Osteosarcoma and related tumors. Cancer Genet Cytogenet 2003; 145: 1-30.
17. Entz-Werle N, Marie-Pierre G, Thomas L, et al. KIT gene in pediatric osteosarcomas: Could it be a new therapeutic target. Int J Cancer 2007; 120: 2510-2516.
18. MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 1989; 81: 935-938.
19. Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995; 18: 93-99.
20. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide improves overall survival-A report from the Children's Oncology Group. J Clin Oncol 2008; 26: 633-638.
21. Finocchiaro LM, Villaverde MS, Gil-Cardeza ML, et al. Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas. Res Vet Sci 2011; 91: 230-234.
22. Daw NC, Neel MD, Rao BN, et al. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Hospital OS99 trial. Cancer 2011; 117: 2770-2778.
23. Cheng YY, Huang L, Lee KM, et al. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 2004; 42: 410-415.
24. Moriceau G, Ory B, Mitrofan L, et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): Pivotal role of the prenylation process. Cancer Res 2010; 70: 10329-10339.
25. Rodriguez CO, Jr., Crabbs TA, Wilson DW, et al. Aerosol gemcitabine: Preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv 2010; 23: 197-206.
26. Jiang M, Pabla N, Murphy RF, et al. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J Biol Chem 2007; 282: 2636-2645.
27. Gokgoz N, Wunder JS, Mousses S, et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 2001; 92: 2181-2189.
28. van Leeuwen IS, Cornelisse CJ, Misdorp W, et al. P53 gene mutations in osteosarcomas in the dog. Cancer Lett 1997; 111: 173-178.
29. Miller CW, Aslo A, Tsay C, et al. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 1990; 50: 7950-7954.
30. Mendoza S, Konishi T, Dernell WS, et al. Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Res 1998; 18: 4449-4453.
31. Mejia-Guerrero S, Quejada M, Gokgoz N, et al. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer 2010; 49: 518-525.
32. Tompkins VS, Hagen J, Frazier AA, et al. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. J Biol Chem 2007; 282: 1322-1333.
33. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: Research tools and potential therapeutics. Cell Cycle 2004; 3: 419-421.
34. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-1893.
35. Zhang J, Chen X, Kent MS, et al. Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor. Mol Cancer Res 2009; 7: 67-78.
36. Hardcastle IR, Liu J, Valeur E, et al. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: Structure-activity studies leading to improved potency. J Med Chem 2011; 54: 1233-1243.
37. Geller DS, Gorlick R. HER-2 targeted treatment of osteosarcoma: The challenges of developing targeted therapy and prognostic factors for rare malignancies. Expert Opin Pharmacother 2010; 11: 51-61.
38. Kolb EA, Gorlick R, Lock R, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 56: 595-603.
39. Coltella N, Manara MC, Cerisano V, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 2003; 17: 1162-1164.
40. Fieten H, Spee B, Ijzer J, et al. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Vet Pathol 2009; 46: 869-877.
41. Mori K, Le Goff B, Berreur M, et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol 2007; 211: 555-562.
42. Levine RA. Overexpression of the sis oncogene in a canine osteosarcoma cell line. Vet Pathol 2002; 39: 411-412.
43. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study. Lancet Oncol 2010; 11: 275-280.
44. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009; 15: 3856-3865.
45. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008; 22: 1301-1309.
46. Freeman SS, Allen SW, Ganti R, et al. Copy number gains in EGFR and copy number losses in PTEN are commons events in osteosarcoma tumors. Cancer 2008; 113: 1453-1461.
47. Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 2002; 39: 372-378.
48. Saxty G, Woodhead SJ, Berdini V, et al. Identification of inhibitors of protein kinase B using fragment-based lead discovery. J Med Chem 2007; 50: 2293-2296.
49. Paoloni MC, Mazcko C, Fox E, et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: A Comparative Oncology Study in dogs. PLoS ONE 2010; 5: e11013.
50. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5: e8.
51. Fossey SL, Liao AT, McCleese JK, et al. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 2009; 9: 81.
52. Onimoe GI, Liu A, Lin L, et al. Small molecules LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs 2011. DOI: 10.1007/s10637-011-9645-1.
53. Knowles HJ, Schaefer KL, Dirksen U, et al. Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: Regulation and phenotypic effects of hypoxia-inducible factor. BMC Cancer 2010; 10: 372.
54. Lugowska I, Woźniak W, Klepacka T, et al. A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma. Pediatr Blood Cancer 2011; 57: 63-68.
55. Zhou Q, Zhu Y, Deng Z, et al. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol 2011; 20: 13-19.
56. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6: 572-577.
57. Gao YS, Mei J, Tong TL, et al. Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice. Cancer Biother Radiopharm 2009; 24: 243-247.
58. Thamm DH, O'Brien MG, Vail DM. Serum vascular endothelial growth factor concentrations and postsurgical outcomes in dogs with osteosarcoma. Vet Comp Oncol 2008; 6: 126-132.
59. Bajpai J, Sharma M, Sreenivas V, et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer 2009; 53: 1035-1039.
60. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study. Ann Oncol 2011. DOI: 10.1093/annonc/mdr151.
61. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10: 182-186.
62. Uchibori M, Nishida Y, Nagasaka T, et al. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 2006; 28: 33-42.
63. Atkinson JM, Falconer RA, Edwards DR, et al. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res 2010; 70: 6902-6912.
64. Eisenach PA, Roghi C, Fogarasi M, et al. MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci 2010; 123: 4182-4193.
65. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004; 92: 77-91.
66. Dong J, Demarest SJ, Sereno A, et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumour response. Mol Cancer Ther 2010; 9: 2593-2604.
67. Khanna C, Prehn J, Hayden D, et al. A randomised controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: Evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res 2002; 8: 2406-2412.
68. Flint AF, U'Ren L, Legare ME, et al. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol 2004; 41: 291-296.
69. Li YG, Geng X. A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma. Eur J Cancer Care (Engl) 2010; 19: 313-316.
70. Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008; 112: 2119-2129.
71. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol 2009; 27: 3148-3153.
72. Sampson ER, Martin BA, Morris AE, et al. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res 2011; 26: 1283-1294.
73. Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005; 27: 611-615.
74. Wakshlag JJ, Balkman CE. Effects of lycopene on proliferation and death of canine osteosarcoma cells. Am J Vet Res 2010; 71: 1362-1370.
75. Carol H, Morton CL, Gorlick R, et al. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55: 1329-1337.
76. Kolb EA, Gorlick R, Maris JM, et al. Combination testing (Stage 2) of the anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2011. DOI: 10.1002/pbc.23157. [Epub ahead of print].
77. Hingorani P, Zhang W, Gorlick R, Kolb EA. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 2009; 15: 3416-3422.
78. Barger AM, Fan TM, de Lorimier LP, et al. Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats. J Intern Vet Med 2007; 21: 133-140.
79. Akiyama T, Choong PF, Dass CR. Rank-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis 2010; 27: 207-215.
80. Lee JA, Jung JS, Kim DH, et al. RANKL expression is related to treatment outcome of patients with localized, high grade osteosarcoma. Pediatr Blood Cancer 2011; 56: 738-743.
81. Wergin MC, Kaser-Hotz B. Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours. In Vivo 2004; 18: 15-19.
82. Yang J, Yang D, Sun Y, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 2011. DOI: 10.1002/cncr.26116. [Epub ahead of print].
83. Loukopoulos P, O'Brien T, Ghoddusi M, et al. Characterisation of three novel canine osteosarcoma cell lines producing high levels of matrix metalloproteinases. Res Vet Sci 2004; 77: 131-141.
84. Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 2000; 61: 111-114.
85. Foukas AF, Deshmukh NS, Grimer RJ, et al. Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br 2002; 84: 706-711.
86. Moore AS, Dernell WS, Ogilvie GK, et al. Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: A randomized, double-blind, placebo-controlled study. J Vet Intern Med 2007; 21: 783-790.
87. Hardcastle IR, Ahmed SU, Atkins H, et al. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem 2006; 49: 6209-6221.
88. Yamaguchi T, Toguchida J, Yamamuro T, et al. Allelotype analysis in osteosarcomas: Frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 1992; 52: 2419-2423.
89. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.